Publications
- Trial Watch: Toll-like receptor agonists in cancer immunotherapy2018 | Second Faculty of Medicine
- Trial Watch: Immunostimulation with Toll-like receptor agonists in cancer therapy2016 | Second Faculty of Medicine
- Trial watch: Dendritic cell-based anticancer therapy2014 | Second Faculty of Medicine
- Classification of current anticancer immunotherapies2014 | Second Faculty of Medicine
- Type I interferon and cancer2024 | Second Faculty of Medicine
- Type I interferon signaling in malignant blasts contributes to treatment efficacy in AML patients2023 | First Faculty of Medicine, Second Faculty of Medicine, Faculty of Medicine in Pilsen
- Targeting tumor-associated macrophages for successful immunotherapy of ovarian carcinoma2023 | First Faculty of Medicine, Second Faculty of Medicine
- Trial watch: chemotherapy-induced immunogenic cell death in oncology2023 | Second Faculty of Medicine
- Interferon signaling restrains renal cell carcinoma heterogeneity2023 | Second Faculty of Medicine
- Safety and efficacy of dendritic cell-based immunotherapy DCVAC/OvCa added to first-line chemotherapy (carboplatin plus paclitaxel) for epithelial ovarian cancer: a phase 2, open-label, multicenter, randomized trial2022 | First Faculty of Medicine, Second Faculty of Medicine, Central Library of Charles University, Third Faculty of Medicine, Faculty of Medicine in Pilsen
Loading network view...